UNITED STATES OF AMERICA
FEDERAL TRADE COMMISSION
WASHINGTON, DC 20580

Office of the Secretary

April 20, 2016

K. Sanders
State of California
Submission No. 00003

Re: *In the Matter of Lupin Ltd., a limited liability corporation; Gavis Pharmaceuticals LLC, a limited liability corporation; and Novel Laboratories, Inc., a corporation;* File No. 151-0202, Docket No. C-4566

Dear K. Sanders:

Thank you for your comment regarding the proposed consent order accepted by the Federal Trade Commission for public comment in the above-captioned matter. The Commission has placed your comment on the public record pursuant to Rule 4.9(b)(6)(ii) of the Commission's Rules of Practice, 16 C.F.R. § 4.9(b)(6)(ii). As we understand your comment, you have concerns about the availability of Gavis Pharmaceuticals' mesalamine ER product. Gavis does not currently offer a mesalamine ER product in the United States, but is expected to launch a product in the near future.

The Commission conducted its non-public review of the above-captioned matter pursuant to its authority under Section 7 of the Clayton Act, 15 U.S.C. § 18, and Section 5 of the Federal Trade Commission Act, 15 U.S.C § 45. As such, the Commission has jurisdiction only to fashion remedies that are required to fix the competitive concerns that arise from violations of federal antitrust law. Accordingly, the Consent Order is designed to address the competitive issues raised by the acquisition.

After careful consideration of your comment, the Commission has determined that the public interest would best be served by issuing the Decision and Order in final form without modification. A copy of the final Decision and Order is enclosed for your information. Relevant materials also are available from the Commission's website at www.ftc.gov.

It helps the Commission's analysis to hear from a variety of sources in its work on antitrust and consumer protection issues, and we appreciate your interest in this matter.

By direction of the Commission.

April J. Tabor
Acting Secretary